Jonathan K. Watts

Jonathan K. Watts

Auto-generated profile, based on publicly available information

Jonathan K. Watts

RNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2017 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
AKAnastasia Khvorova
Anastasia Khvorova
JWJonathan K Watts
Jonathan K Watts
Refinements in the chemistries employed in oligonucleotide therapeutics have galvanized clinical progress. The complex interplay between chemical modifications and integration into sequence architecture is discussed in the context of antisense and small-interfering RNA drugs. After nearly 40 years of development, oligonucleotide therapeutics are nearing meaningful clinical productivity. One of the key advantages of oligonucleotide drugs is that their delivery and potency are derived primarily from the chemical structure of the oligonucleotide whereas their target is defined by the base sequence. Thus, as oligonucleotides with a particular chemical design show appropriate distribution and safety profiles for clinical gene silencing in a particular tissue, this will open the door to the rapid development of additional drugs targeting other disease-associated genes in the same tissue. To achieve clinical productivity, the chemical architecture of the oligonucleotide needs to be optimized with a combination of sugar, backbone, nucleobase, and 3′- and 5′-terminal modifications. A portfolio of chemistries can be used to confer drug-like properties onto the oligonucleotide as a whole, with minor chemical changes often translating into major improvements in clinical efficacy. One outstanding challenge in oligonucleotide chemical development is the optimization of chemical architectures to ensure long-term safety. There are multiple designs that enable effective targeting of the liver, but a second challenge is to develop architectures that enable robust clinical efficacy in additional tissues.

7 September 2011 in The Journal of Pathology
Verified
Journal Article
Open access
PDF file
JWJonathan K Watts
Jonathan K Watts
DCDavid R Corey
David R Corey
Synthetic nucleic acids are commonly used laboratory tools for modulating gene expression and have the potential to be widely used in the clinic. Progress towards nucleic acid drugs, however, has been slow and many challenges remain to be overcome before their full impact on patient care can be understood. Antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) are the two most widely used strategies for silencing gene expression. We first describe these two approaches and contrast their relative strengths and weaknesses for laboratory applications. We then review the choices faced during development of clinical candidates and the current state of clinical trials. Attitudes towards clinical development of nucleic acid silencing strategies have repeatedly swung from optimism to depression during the past 20 years. Our goal is to provide the information needed to design robust studies with oligonucleotides, making use of the strengths of each oligonucleotide technology. Copyright © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

1 October 2014 in Molecular Cell
Verified
Journal Article
Closed access
KSKatie Schaukowitch
Katie Schaukowitch
JJJae-Yeol Joo
Jae-Yeol Joo
XLXihui Liu
Xihui Liu
JWJonathan K. Watts
Jonathan K. Watts
CMCarlos Martinez
Carlos Martinez
TKTae-Kyung Kim
Tae-Kyung Kim

1 October 2008 in Drug Discovery Today
Verified
Journal Article
Closed access
JWJonathan K. Watts
Jonathan K. Watts
GDGlen F. Deleavey
Glen F. Deleavey
MDMasad J. Damha
Masad J. Damha

23 December 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
HTHélène Tran
Hélène Tran
MMMichael P. Moazami
Michael P. Moazami
HYHuiya Yang
Huiya Yang
DMDiane McKenna-Yasek
Diane McKenna-Yasek
CDCatherine L. Douthwright
Catherine L. Douthwright
RBRobert H. Brown
Robert H. Brown

6 July 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
AMAamir Mir
Aamir Mir
JAJulia F. Alterman
Julia F. Alterman
MHMatthew R. Hassler
Matthew R. Hassler
ADAlexandre J. Debacker
Alexandre J. Debacker
EHEdward Hudgens
Edward Hudgens
ESErik J. Sontheimer
Erik J. Sontheimer
RNA-based drugs depend on chemical modifications to increase potency and to decrease immunogenicity in vivo. Chemical modification will likely improve the guide RNAs involved in CRISPR-Cas9-based therapeutics as well. Cas9 orthologs are RNA-guided microbial effectors that cleave DNA. Here, we explore chemical modifications at all positions of the crRNA guide and tracrRNA cofactor. We identify several heavily modified versions of crRNA and tracrRNA that are more potent than their unmodified counterparts. In addition, we describe fully chemically modified crRNAs and tracrRNAs (containing no 2′-OH groups) that are functional in human cells. These designs will contribute to Cas9-based therapeutics since heavily modified RNAs tend to be more stable in vivo (thus increasing potency). We anticipate that our designs will improve the use of Cas9 via RNP and mRNA delivery for in vivo and ex vivo purposes.